Romark Laboratories, L.C. Romark Laboratories, L.C. Romark Laboratories, L.C. Romark Laboratories, L.C. Romark Laboratories, L.C.

News & Events


Romark Laboratories Adds Alan Burns As Vice President Of Quality

New VP Quality to Manage Romark’s Global Corporate Quality Functions

TAMPA, Fla. – August 19, 2014 – Romark Laboratories announced today that Alan Burns has joined the company as Vice President, Quality. Alan brings more than twenty years of experience in Quality with companies including Baxter Healthcare, Monsanto, Abbott Laboratories, Eli Lilly & Co. and Bayer Healthcare. Most recently, he was Vice President Global Quality with Sartorius Stedim Biotech.

"We are excited to have Alan join our company," said Marc Ayers, President and Chief Executive Officer of Romark. "He brings a wealth of expertise and experience, and importantly, he shares our company’s commitment to excellence in everything we do. As we continue to grow, our dedication and ability to deliver Quality will be critical to our success. Alan will be instrumental in helping us achieve our corporate objectives."

Alan will manage a growing team of Quality professionals in the United States and at the Company’s API (active pharmaceutical ingredient) manufacturing facility, Lapicor NV, in Belgium.

With the addition of Alan Burns, Romark continues to build infrastructure to support the growth and development of its business. The company has grown from approximately 50 to 150 employees worldwide since the middle of 2013.

About Romark Laboratories

Romark Laboratories, L.C. is a vertically integrated biopharmaceutical company committed to the discovery and development of innovative small molecule drugs for treating infectious diseases and cancers. The Company markets Alinia® (nitazoxanide) tablets, 500 mg in the United States through a specialty sales force focused on gastroenterologists and primary care physicians.

Romark is developing a class of small molecule drugs called thiazolides. The Company’s product, NT-300 (nitazoxanide), is presently undergoing Phase 3 clinical development on a global basis for treatment of acute uncomplicated influenza. The NT-300 development program is being conducted under contract HHSO100201300004C with the U.S. Department of Health and Human Services. Other new drugs from the Company’s platform technology are proposed for treatment of viral diseases and cancers.